Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial-Reference-Cited by-同舟云学术

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Published:2014-06 Issue:6 Volume:25 Page:1128-1136
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bonnefoi H.,Litière S.,Piccart M.,MacGrogan G.,Fumoleau P.,Brain E.,Petit T.,Rouanet P.,Jassem J.,Moldovan C.,Bodmer A.,Zaman K.,Cufer T.,Campone M.,Luporsi E.,Malmström P.,Werutsky G.,Bogaerts J.,Bergh J.,Cameron D.A.

Funder

US National Cancer Institute

French Ligue Nationale Contre le Cancer and Cancer Research UK

SIRIC BRIO

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/6/1128/16702913/mdu118.pdf

Reference15 articles.

1. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial;Bonnefoi;Lancet Oncol,2011